For & Against

Claude View

What's Next

The market will focus on two things in the next 90 days: whether Q4 FY2026 NII sustains above ₹430 Cr (confirming the H2 acceleration was structural, not seasonal), and any developments from the CVC recruitment probe. The Q4 print matters more than usual because 9M annualized EPS of ~₹74 would put the stock at under 12x forward earnings – a level that demands either a growth re-rating or a governance de-rating, but not the current limbo.

The RBI easing cycle (125 bps cut since Feb 2025, repo at 5.25%) is already the most aggressive since 2019. Can Fin has passed through ~50 bps on the asset side while funding costs are repricing lower on NCD and term loan rollovers. If the cycle resumes in H2 2026, NIM could expand toward 4.2-4.3% – a meaningful earnings tailwind. But the April pause signals the easy cuts are done; the rest depends on geopolitics.

For / Against / My View

For

The highest-ROE HFC trades at a value-tier multiple. Can Fin delivers 18.2% ROE – the best in the listed HFC peer set – yet trades at 11.7x earnings and 2.1x book. Aptus, with a comparable 18.6% ROE, trades at 13.9x PE and 2.7x PB. HomeFirst at 16.5% ROE commands 23.4x PE. The scatter plot from Quant's analysis shows Can Fin sitting alone in the bottom-right quadrant (high ROE, low PE). Even a modest re-rating to 14x earnings on FY26E EPS of ~₹74 implies ₹1,036 – 21% above the current ₹859.

NII acceleration is real and rate-cycle-driven. Quarterly NII jumped from ₹350-372 Cr in Q3-Q1 FY26 to ₹410-431 Cr in Q2-Q3 FY26 – a step-change after five flat quarters. This is not accounting noise: 100% of bank borrowings are now repo-linked (completed FY25), and the 125 bps repo cut is flowing through the liability side while asset yields are stickier. Spread expanded from 2.56% to 2.89% in Q3 FY26. The mechanism is clear and has 2-3 more quarters to run.

FII accumulation signals institutional conviction. Foreign institutional holdings rose from 10.7% to 13.4% over 8 quarters – quiet, steady buying while DIIs trimmed. Morgan Stanley maintains Overweight with a ₹1,000 target. This is not a crowded or consensus trade.

Excess capital removes dilution risk. CAR at 25.08% (vs 15% regulatory minimum) funds 3-4 years of 15% book growth without raising equity. The company is returning more capital (payout ratio jumped to 19% in FY25) because it generates more than it needs. No equity overhang.

Against

Three governance incidents in four years is a pattern, not bad luck. Bhilwara fraud (2022, fake ITRs in 37 loans), Ambala fraud (2023, ₹38.5 Cr employee embezzlement over 2 years), and now a court-ordered CVC recruitment probe (April 2026) where a whistleblower alleges hiring manipulation by a senior GM with Canara Bank board influence. Sherlock grades governance B-. The CVC probe is live and binary: if it implicates Canara Bank nominees, the promoter-subsidiary relationship – which underpins the AAA rating and cheap funding – comes under structural question.

Nobody running this company owns it. The MD holds 100 shares. The Deputy MD holds zero (Canara Bank depute). All independent directors hold zero. The ESOP 2024 scheme is a step forward but covers only 0.13% of shares and has not vested. Three CFOs in 2.5 years adds to the organizational fragility. When governance stress arrives – as it has three times now – there is no personal wealth at stake to anchor decision-making.

AUM growth guidance has missed three consecutive years. FY24: guided 15%, delivered 10.9%. FY25: guided 15-16%, delivered 9.2%. FY26: guided 15%, tracking 11-12%. Each miss had a plausible external explanation (Ambala, Karnataka e-khata, Telangana), but as Historian notes, the pattern is consistent. The "Vision 2028" aspiration of ₹1.3 lakh Cr AUM has been quietly shelved. A business that compounds at 10-11% deserves a different multiple than one compounding at 15%.

The SENP mix shift changes the risk character. Management is actively pushing self-employed borrowers from 29% toward 35% of the book to boost yields. Warren flags that SENP GNPA runs 1.5-1.7% vs sub-0.5% for salaried. GNPA has already drifted from 0.55% (Q4 FY23) to 0.87-0.98%. If GNPA breaches 1.5% as SENP scales, the 2%+ ROA advantage – the real engine of the 18% ROE – disappears, and the stock de-rates toward LIC Housing multiples (5-6x PE).

My View

This is a close call that tilts slightly toward the bulls, but not enough to act with conviction today. The NII acceleration and rate-cycle tailwind are genuine and mechanically sound – this is not a hope trade, it is a spread business entering the favorable part of its cycle. What holds me back is the governance pattern: three incidents in four years, a live CVC probe, near-zero insider ownership, and a PSU-parent dynamic that introduces risks no amount of spread arithmetic can offset. I would lean toward starting a small position if Q4 FY2026 confirms NII above ₹430 Cr and GNPA stays below 1.0%, but I would want the CVC outcome before building further. The single data point that would flip this to a clear buy: CVC clears the probe with no material findings and Iyer meaningfully increases his personal shareholding. Until then, the discount to peers is earned, not anomalous.